Journal article
Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma
S Sandhu, CM McNeil, P LoRusso, MR Patel, O Kabbarah, C Li, S Sanabria, WM Flanagan, RF Yeh, F Brunstein, D Nazzal, R Hicks, V Lemahieu, R Meng, O Hamid, JR Infante
Investigational New Drugs | SPRINGER | Published : 2020
Abstract
Background Endothelin B receptor (ETBR) is involved in melanoma pathogenesis and is overexpressed in metastatic melanoma. The antibody-drug conjugate DEDN6526A targets ETBR and is comprised of the humanized anti-ETBR monoclonal antibody conjugated to the anti-mitotic agent monomethyl auristatin E (MMAE). Methods This Phase I study evaluated the safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DEDN6526A (0.3–2.8 mg/kg) given every 3 weeks (q3w) in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma. Results Fifty-three patients received a median of 6 doses of DEDN6526A (range 1–49). The most common drug-related adverse events (>25% across dose ..
View full abstract